KR20190110683A - Composition for preventing, treating or improving obesity comprising Eupatilin - Google Patents

Abstract

The present invention relates to a composition for preventing, treating, or alleviating obesity, comprising eupatilin, wherein the eupatilin has an effect of inhibiting the differentiation of adipocytes and reducing lipid accumulation in cells. In addition, by inhibiting the expression of peroxysome proliferative activator receptor gamma (PPARγ) and CCAAT-enhancer binding protein alpha (C/EBPα) and adiponectin, which are transcription factors involved in adipocyte formation and differentiation to inhibit fat production, it is possible to exhibit an excellent antiobesity effect. Therefore, eupatilin of the present invention can be usefully used as a pharmacetucial composition and health functional food for preventing, treating or alleviating obesity.

Description

Composition for preventing, treating or improving obesity comprising Eupatilin

The present invention relates to a composition for preventing, treating or improving obesity, which comprises eupatillin as an active ingredient.

Obesity generally means that the body has an excessive amount of fat tissue, and the energy consumed by food is not balanced with the energy consumed by physical activity, so that surplus energy is accumulated as body fat. Obesity can be caused by a wide variety of causes, including genetic factors, irregular eating habits, lack of exercise, or environmental effects from Western diets, depression, boredom, psychological effects from excessive stress, and pathological factors caused by thyroid or corticosteroid changes. It is known to be caused by. Recently, many changes in eating habits have occurred due to economic growth and lifestyle changes, and the busy modern people are increasing overweight and obesity due to high calorie diets such as fast food and low exercise.

In addition, since obesity is caused by the hypertrophy of adipocytes, inhibition of adipocyte differentiation may be helpful in the treatment of obesity (Henninger, Eliasson, Jenndahl, & Hammarstedt, 2014). In the past, anti-obesity studies related to the inhibition of adipocyte differentiation and lipid accumulation have been reported (Kim & Lee, 2017; Li et al., 2017), where 3T3-L1 mouse fibroblasts are responsible for the differentiation of adipocytes. A well-characterized model for the study is commonly used in in vitro studies (Kaestner et al., 1989; SK Kim & Kong, 2010).

Obesity is more serious than its own risks because of the many complications that can be caused by obesity.If body fat is abnormally increased due to energy imbalance over time, diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis And various metabolic diseases such as fatty liver and adult disease. In addition, obesity can cause not only physical illness but also mental illness such as social isolation, alienation, lack of self-confidence and depression, which is a serious social problem not only in the West but also in Korea, and the need for prevention and treatment of obesity is very important. Is recognized.

Obesity can be treated with diet, regular exercise, lifestyle improvements such as behavioral therapy, and medications such as appetite suppressants and fat absorption inhibitors. Obesity is a chronic disease that requires long-term use when attempting medication. Currently, products approved for long-term use in Korea for more than three months include sibutramine, an appetite suppressant, and orlistat, an lipase inhibitor. There is). However, most of these anti-obesity drugs are psychotropic drugs that act on the central nervous system to control appetite, so they have side effects such as headache and vomiting and there are problems such as abuse. Therefore, researches are being actively conducted to develop materials having high stability and excellent anti-obesity effect that can solve side effects of the commercially available anti-obesity agents.

Meanwhile, Eupatilin is Artemisia. As the main flavonoid compound of the genus, it is known to have anti-cancer and anti-oxidant effects, and has been shown to have an anti-gastric and anti-ulcer effect as a therapeutic agent for gastrointestinal diseases (see Korean Patent No. 127777). The anti-obesity effect is still unknown.

Thus, the inventors of the present invention confirmed that the eupatylin exhibits excellent anti-obesity effect by inhibiting adipogenesis in 3T3-L1 adipocytes, so that it can be used as a composition for preventing, treating, or improving obesity.

The present inventors have tried to develop a composition for preventing or treating obesity, which has high stability and excellent anti-obesity effect that can solve the problems of the conventional anti-obesity agent, and confirms that the eupatin of the present invention has an excellent anti-obesity effect and the present invention Was completed.

Accordingly, an object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity, including eupatini as an active ingredient.

In addition, an object of the present invention is to provide a dietary supplement for the prevention or improvement of obesity containing eupatini as an active ingredient.

However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problem, another task that is not mentioned will be clearly understood by those skilled in the art from the following description.

In order to achieve the above object, the present invention provides a pharmaceutical composition for the prevention or treatment of obesity, including eupatini as an active ingredient.

The present invention also provides a dietary supplement for preventing or improving obesity, including eupatini as an active ingredient.

In one embodiment of the present invention, the composition can inhibit the differentiation of adipocytes.

In another embodiment of the present invention, the composition may reduce lipid accumulation in cells.

In another embodiment of the present invention, the composition may inhibit the expression of a transcription factor or adiponectin involved in adipocyte formation and differentiation.

In another embodiment of the present invention, the transcription factor may be peroxysome proliferator activated receptor gamma (PPARγ) or CCAAT-enhancer binding protein alpha (C / EBPa).

The present invention also provides a method for preventing or treating obesity, comprising administering the composition to a subject.

In addition, the present invention provides a preventive or therapeutic use of the composition.

Eupatillin according to the present invention has the effect of inhibiting the differentiation of adipocytes and reduce the accumulation of lipids in the cells, peroxysome proliferator activator receptor gamma (PPARγ) and CCAAT- which are transcription factors involved in adipocyte formation and differentiation It was confirmed that the anti-obesity effect was excellent by inhibiting the expression of enhancer binding protein alpha (C / EBPa) and adiponectin, and thus, the eupatiliin of the present invention has a pharmaceutical composition and health for preventing, treating, or improving obesity. It is expected to be used in various fields such as nutraceuticals.

1 is a diagram showing the results of measuring cell viability in 3T3-L1 adipocytes treated with eupatillin according to an embodiment of the present invention by MTT analysis.
Figure 2 shows the results of observing the cell shape of the 3T3-L1 adipocytes, negative control (NC), and positive control (PC) treated with eupatillin according to an embodiment of the present invention using a 400x magnification microscope. The figure shown.
Figure 3a is a view showing the result of Oil Red O staining in 3T3-L1 adipocytes treated with eupatillin according to an embodiment of the present invention.
Figure 3b is a view showing the measurement of the content of Triglyceride (TG) in 3T3-L1 adipocytes treated with eupatillin according to an embodiment of the present invention.
Figure 4a is a diagram showing the mRNA expression level of PPARγ, C / EBPa, and adiponectin by the treatment of eupatillin in 3T3-L1 adipocytes according to an embodiment of the present invention.
Figure 4b is a view showing the expression level of PPARγ, C / EBPa, and adiponectin protein by the treatment of eupatillin in 3T3-L1 adipocytes according to an embodiment of the present invention.

As the invention allows for various changes and numerous embodiments, particular embodiments will be illustrated in the drawings and described in detail in the written description. However, this is not intended to limit the present invention to specific embodiments, it should be understood to include all transformations, equivalents, and substitutes included in the spirit and scope of the present invention. In the following description of the present invention, if it is determined that the detailed description of the related known technology may obscure the gist of the present invention, the detailed description thereof will be omitted.

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for the prevention or treatment of obesity, including eupatini as an active ingredient.

The obesity, which is a disease to be prevented or treated according to the present invention, refers to a state in which fat cells proliferate and differentiate due to metabolic disorders, and thus fat is excessively accumulated, and hypertension, diabetes mellitus, and dyslipidemia Associated complications, including metabolic syndrome, may be caused. When energy absorption increases relative to consumption, the mass and volume of fat cells increase, resulting in an increase in the mass of fat tissue.

As used herein, the term "prevention" means any action that inhibits obesity or delays the onset by administration of a pharmaceutical composition according to the invention.

As used herein, the term "treatment" refers to any action by which administration of the pharmaceutical composition according to the present invention improves or advantageously alters the symptoms of obesity.

The present invention also provides a method for preventing or treating obesity, comprising administering the pharmaceutical composition to a subject.

As used herein, the term "administration" means providing a subject with any of the compositions of the present invention in any suitable manner.

As used herein, the term "individual" refers to a subject in need of treatment of a disease, and more specifically, human or non-human primates, mice, dogs, cats, horses, cattle, and the like. Mean mammal.

Eupatillin according to the present invention can inhibit the differentiation of adipocytes and reduce lipid accumulation in adipocytes. In addition, expression of a transcription factor or adiponectin involved in adipocyte formation and differentiation can be suppressed. At this time, the transcription factor may be, but is not limited to, peroxysome proliferator activator receptor gamma (PPARγ) or CCAAT-enhancer binding protein alpha (C / EBPa).

In one experimental example of the present invention, during the differentiation period of 3T3-L1 adipocytes, and after observation through a microscope after the treatment of eupatillin, it was confirmed that the eupatylin strongly inhibits the differentiation of 3T3-L1 adipocytes in a concentration-dependent manner. (See Example 2 and FIG. 2).

In another experimental example of the present invention, as a result of lipid staining in 3T3-L1 adipocytes using Oil red O staining experiments, lipid droplets and triglycerides in 3T3-L1 adipocytes treated with eufatlin Accumulation of (Triglyceride, TG) was confirmed that the concentration-dependent decrease compared to the positive control group (PC), which is fully differentiated adipocytes (see Example 3 and Figures 3a-b).

In another experimental example of the present invention, as a result of synthesizing RNA isolated from 3T3-L1 adipocytes treated with eupatillin with cDNA and proceeding with RT-PCR, eupatillin was synthesized from PPARγ, C / EBPa, and adiponectin. It was confirmed to suppress mRNA expression concentration dependently (see Example 4-1 and Figure 4a).

In addition, as a result of analyzing protein expression in 3T3-L1 adipocytes treated with eupatillin, it was confirmed that eupatillin inhibits PPARγ, C / EBPa, and adiponectin protein expression (see Example 4-2 and FIG. 4B). .

Differentiation of adipocytes is regulated by changes in expression of various transcription factors such as peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT-enhancer-binding protein alpha (C / EBPα) (Yoo, Seo, Shin, & Jeong, 2015 ).

At this time, the peroxisome proliferator-activated receptor gamma (PPARγ) is an important factor in the cell signaling pathway and is known to regulate transcription factors related to glucose metabolism and adipocyte formation. PPARγ is expressed in the form of PPARγ1 and PPARγ2 in adipocytes. PPARγ2 has 30 more amino acids at the N-terminus than PPARγ1, but the remaining amino acid sequences are the same, and the expression levels of PPARγ1 and PPARγ2 differ from tissue to tissue. PPARγ2 is specifically expressed in adipocytes, while PPARγ1 is expressed at low levels in several cell types such as macrophages, colonic epithelial cells, and endothelial cells (Lehrke & Lazar, 2005; Sarjeant & Stephens, 2012). PPARγ2 can have a significant effect on adipogenesis and has been found in adipocytes of obese patients (Ren, Collingwood, Rebar, Wolffe, & Camp, 2002; Sarjeant & Stephens, 2012).

CCAAT-enhancer-binding protein alpha (C / EBPα) is a protein that plays a pivotal role with PPARγ in regulating the differentiation of adipocytes. In the process of differentiating progenitor cells, the early stages of C / EBPδ and C / EBPβ induce the expression of PPARγ, and the increased expression of PPARγ is responsible for the late stage of differentiation of adipocytes by C / EBPa expression.

Adiponectin is also adipokine secreted by adipocytes and has been reported to control insulin resistance-related obesity (Lindsay et al., 2002).

On the other hand, the "pharmaceutical composition" in the present invention means that is prepared for the purpose of preventing or treating a disease, each can be used in formulated in various forms according to conventional methods. For example, it may be formulated in oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, and syrups, and may be formulated in the form of external preparations, suppositories, and sterile injectable solutions.

The pharmaceutical composition according to the present invention may include a pharmaceutically acceptable carrier in addition to the active ingredient. At this time, the pharmaceutically acceptable carrier is commonly used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose , Polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. In addition to the above components, it may further include a lubricant, wetting agent, sweetener, flavoring agent, emulsifier, suspending agent, preservative and the like.

The pharmaceutical compositions of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is determined by the condition and weight of the patient, Depending on the extent, drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level refers to the type of disease, the severity, the activity of the drug, It may be determined according to the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of treatment, factors including the drug used concurrently and other factors well known in the medical field. The pharmaceutical compositions according to the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with a minimum amount without side effects, which can be readily determined by one skilled in the art.

In another aspect, the present invention provides a dietary supplement for preventing or improving obesity comprising eupatillin as an active ingredient.

As used herein, the term "improvement" refers to any action that at least reduces the parameters associated with the condition being treated, for example the extent of symptoms. At this time, the health functional food composition may be used simultaneously or separately with the agent for treatment before or after the onset of the disease for the prevention or improvement of obesity.

In the present invention, the "health food composition" is characterized in that it is formulated as one selected from the group consisting of tablets, pills, powders, granules, powders, capsules and liquid formulations, including one or more of carriers, diluents, excipients and additives. It is done.

Examples of the food that can be added to the eupatini of the present invention include various foods, powders, granules, tablets, capsules, syrups, beverages, gums, teas, vitamin complexes, and health functional foods. As additives which may be further included in the present invention, natural carbohydrates, flavoring agents, nutrients, vitamins, minerals (electrolytes), flavoring agents (synthetic flavoring agents, natural flavoring agents, etc.), colorants, fillers, pactic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonation agents, and one or more components selected from the group consisting of pulp can be used. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the flavoring agent, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.

In addition to the above, the composition according to the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and neutralizing agents, fact acids and salts thereof, alginic acid and salts thereof, organic acids, protection Sex colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages and the like.

In addition, other compositions of the present invention may contain pulp for the production of natural fruit juices and vegetable beverages. These components can be used independently or in combination.

Specific examples of the carrier, excipient, diluent and additives include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, Group consisting of microcrystalline cellulose, polyvinylchirrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water, sugar syrup, methyl hydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, and mineral oil It is preferred that at least one selected from be used.

Hereinafter, preferred embodiments and experimental examples of the present invention will be described in detail with reference to the accompanying drawings. However, these Examples and Experimental Examples are only for illustrating the present invention, and the scope of the present invention will not be construed as being limited by these Examples and Experimental Examples.

Example 1 . Sample Preparation and Cell Culture

Eufatlin was purchased from LKT Laboratories (St. Paul, MN, USA) and DMEM fetal bovine serum (FBS), neonatal calf serum (NBCS) and DMEM medium were purchased from Gibco Life Technologies (Grand Island, NY, USA). Insulin, indomethacin, dexamethasone, IBMX, Oil Red O solution was purchased from Sigma-Aldrich (St. Louis, MO, USA) and MTT was purchased from Amresco (Solon, OH, USA). Triglyceride quantitative color / fluorescence measurement kit was purchased from BioVision (Milpitas, CA, USA), primers from Macrogen (Seoul, Korea) and cDNA synthesis kit from TaKaRa Bio (Otsu, Shiga, Japan). Antibodies against C / EBPa and β-actin were purchased from Cell Signaling Technology (Beverly, MA, USA) and Santa Cruz Biotechnology (Santa Cruz, CA, USA) respectively, and PPARγ, adiponectin antibodies were Abcam plc (Cambridge, UK) Purchased from

Mouse 3T3-L1 adipocytes were purchased from the Korea Cell Line Bank (Seoul, Korea). They were maintained in DMEM supplemented with 10% NBCS, antibiotic (1% penicillin / streptomycin) (5% humidity, 37 ° C., CO ₂ incubator). After 2 days, cells were exposed to differentiation medium (MDI) consisting of DMEM containing 10% FBS, IBMX (0.5 mM), insulin (10 μg / ml), dexamethasone (1 μM) and indomethacin (100 μM) I was. After 2 days, the culture medium was replaced with DMEM supplemented with 10% FBS and insulin every other day (day 2 to day 8).

Experimental Example 1. Cell Viability  Measure

3T3-L1 cells were seeded in 96-well plates at a concentration of 2 × 10 ³ cells per well. After incubation for 24 hours, the cells were treated with eupatini (20 or 40 μM). 24 or 48 hours after incubation, respectively, media was removed and MTT solution (0.5 mg / ml) was added. After incubation for 3 hours, isopropanol was added and absorbance was measured at 495 nm using a spectrophotometer.

As a result, as shown in Figure 1, eupatini did not significantly affect the viability of 3T3-L1 adipocytes at concentrations of 20 and 40 μM.

Experimental Example  2. Eufatlin  Confirmation of fat cell differentiation inhibitory effect

During the differentiation of 3T3-L1 adipocytes in Example 1 treated or untreated eupatylin (20 or 40 μM), after differentiation was completed, it was observed through a microscope of 400x magnification and shown in FIG. When 3T3-L1 adipocytes cultured with eupatillin were compared with the negative control group (NC) using adipocytes and the positive control group (PC) using fully differentiated adipocytes, the eutatilin concentration-dependent 3T3-L1 It was confirmed to strongly inhibit adipocyte differentiation.

Experimental Example  3. Eufatlin  Confirmation of Intracellular Lipid Accumulation Reduction

During the 3T3-L1 adipocyte cell differentiation period in Example 1, eupatylin (20 or 40 μM) was treated or untreated to complete differentiation, washed with 20% isopropanol and fixed with 5% formalin for 1 hour. In addition, intracellular lipid droplets were stained with Oil Red O solution for 15 minutes and then dissolved in 100% isopropanol. The absorbance of each sample was measured at 495 nm.

In addition, triglyceride (TG) quantification was confirmed by measuring the total amount of TG using triglyceride colorimetric colorimetric / fluorescence measurement kit (Biovision) according to the manufacturer's protocol. The 3T3-L1 cells treated or untreated with eupatillin (20 or 40 μM) were homogenized in TG assay buffer containing 5% Nonidet P40 and then heated to 80 ° C. for the last 4 minutes. Thereafter, the mixture was centrifuged for 2 minutes to remove insoluble matter, diluted with dH ₂ O, mixed with the TG reaction mixture, and incubated for 1 hour at room temperature. Colorimetric intensity was measured at 570 nm.

As a result, as shown in FIGS. 3A and 3B, the accumulation of lipid droplets (FIG. 3A) and triglyceride (TG) in 3T3-L1 adipocytes (FIG. 3B) was positive for fully differentiated adipocytes. Compared with the control (PC), it was confirmed that the concentration-dependent decrease in 3T3-L1 adipocytes treated with 20 and 40 μM of eufatlin.

Therefore, it can be seen from the above results that eupatillin reduces the accumulation of lipids in cells during the differentiation of 3T3-L1 adipocytes into mature adipocytes.

Experimental Example  4. Eufatlin  Transcription factors related to adipocyte formation and differentiation, and Adiponectin  Confirmation of expression suppression effect

4-1. mRNA  Expression analysis

After completion of the differentiation by treatment or non-treatment with eupatyline (20 or 40 μM) during 3T3-L1 adipocyte cell differentiation period in Example 1, total cell RNA was extracted using RNAiso plus (Takara). Reverse transcription and synthesis of cDNA were performed using the PrimeScript ™ RT cDNA Synthesis Kit (Takara) according to the manufacturer's protocol. qPCR reagent was used as EmeraldAmp GT PCR Master Mix (Takara). Quantitative RT-PCR was performed with the iCycler iQ ™ Real-Time PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA) using SYBR Green (TOYOBO, Osaka, Japan). Primer type and sequence of the detected genes are shown in Table 1.

As a result, as shown in FIG. 4A, it was found that eupatillin suppresses mRNA expression of PPARγ, C / EBPa, and adiponectin in a concentration-dependent manner.

4-2. Protein expression analysis

During the 3T3-L1 adipocyte cell differentiation period in Example 1, eupatyline (20 or 40 μM) was treated or untreated to differentiate, and then lysed using RIPA lysis buffer (Biosesang, Korea). Equal amounts of protein were separated on 12% sodium dodecylsulphite polyacrylamide gel. The separated protein was transferred to nitrocellulose membrane, blocked with 5% skim milk (10 mmol / L Tris pH 8.0, 150 mmol / L NaCl, 0.05% Tween 20) for 1 hour in TBST, followed by PPARγ, C / EBPa, Incubated overnight at 4 ° C with primary antibody against adiponectin. After washing with TBST, the membrane was incubated with HRP-conjugated secondary antibody for 1 hour at room temperature and the protein was detected using enhanced chemiluminescence (ECL) reagent (GE Healthcare, Buckinghamshire, UK).

As a result, it was confirmed that eupatillin inhibits PPARγ, C / EBPa, and adiponectin protein expression, as shown in Fig. 4B.

Example  2. Statistical Analysis

Statistical analysis of all experiments was performed using SPSS version 20.0 (SPSS Inc., Chicago, IL). Statistical differences were analyzed using one-way ANOVA. P values of <0.05 were considered significant.

The specific parts of the present invention have been described in detail above, and it is apparent to those skilled in the art that such specific descriptions are merely preferred embodiments, and thus the scope of the present invention is not limited thereto. something to do. Thus, the substantial scope of the present invention will be defined by the appended claims and their equivalents.

Claims (10)

Eupatilin as an active ingredient, obesity prevention or treatment pharmaceutical composition.
The method of claim 1,
The composition is characterized in that to inhibit the differentiation of fat cells, obesity prevention or treatment pharmaceutical composition.
The method of claim 1,
The composition is characterized in that to reduce the accumulation of lipids in the cell, obesity prevention or treatment pharmaceutical composition.
The method of claim 1,
The composition is characterized in that to suppress the expression of a transcription factor or adiponectin involved in adipocyte formation and differentiation, obesity prevention or treatment pharmaceutical composition.
The method of claim 4, wherein
The transcription factor is characterized in that the peroxysomal proliferator activator receptor gamma (PPARγ) or CCAAT-enhancer binding protein alpha (C / EBPa), a pharmaceutical composition for preventing or treating obesity.
Eufattiline as an active ingredient, obesity prevention or improvement health functional food composition.
The method of claim 6,
The composition is characterized in that to inhibit the differentiation of fat cells, obesity prevention or improvement health functional food composition.
The method of claim 6,
The composition is characterized in that to reduce the accumulation of lipids in the cell, health food composition for preventing or improving obesity.
The method of claim 6,
The composition is characterized in that to suppress the expression of transcription factors or adiponectin involved in adipocyte formation and differentiation, obesity prevention or improvement health functional food composition.
The method of claim 9,
The transcription factor is characterized in that the peroxysomal proliferator activator receptor gamma (PPARγ) or CCAAT-enhancer binding protein alpha (C / EBPa), obesity prevention or improvement health functional food composition.

Images